ArticleAntioxidants (Basel, Switzerland)2026
Tacrolimus Inhibits Hepatic Ferroptosis Through Modulating SIRT7-Dependent NRF2 Activation in Diabetes.
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatic lipotoxicity in type 2 diabetes promotes oxidative stress and ferroptosis, driving progressive liver injury, for which effective targeted therapies remain lacking. Here, we identify tacrolimus (TAC), a clinically established immunosuppressant, as an unexpected suppressor of hepatic ferroptosis in db/db diabetic mice. TAC administration markedly alleviated liver injury, fibrosis, and inflammation, accompanied by reduced oxidative stress and ferroptosis signatures. Transcriptomic profiling revealed enrichment of glutathione metabolism pathways in livers of TAC-treated db/db diabetic mice. Mechanistically, TAC inhibited ferroptosis in primary hepatocytes by activating the NRF2 pathway, increasing NRF2 protein abundance and its nuclear translocation in an SIRT7 deacetylase activity-dependent manner. Together, these findings uncover a previously unrecognized role of TAC in repressing ferroptosis through the SIRT7-NRF2 axis, highlighting ferroptosis modulation by TAC as a potential therapeutic strategy for diabetic liver diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.